59%
Sleep Increase
Within 130 minutes of administration
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Sleep & Recovery Peptide
DSIP
Delta-Sleep PeptideEmideltide
A 9-amino acid peptide that modulates delta-wave sleep architecture and circadian rhythm signaling, studied for sleep onset mechanisms in research models. Premium Research Peptide.
Dosage
Quantity
1
$49.99
4 interest-free payments of $12.50We accept
DSIP$49.99
Free shippingon orders over $150
30-day money-backguarantee
Secure checkout256-bit SSL
97%
Symptom Relief
Opiate withdrawal (107 patients)
86%
Pain Reduction
Chronic pain patients (6/7)
NoLD50
Safety Record
No lethal dose ever determined
9amino acids
Nonapeptide
WAGGDASGE sequence
How DSIP Works
The Science, Simplified
Natural Sleep Programming
DSIP is synthesized in the hypothalamus and targets multiple sites in the brainstem. Unlike sedatives, it promotes natural sleep architecture by modulating circadian rhythms, neurotransmitters, and stress-response systems — without causing dependence or tolerance.
CIRCPrimary
Circadian Pathway
Circadian Rhythm Modulation
Regulates sleep-wake cycles
Normalizes disturbed sleep patterns
Effects persist for days after dosing
OPIModerate
Opioid Pathway
Endogenous Opioid System
Modulates pain perception
Blocked by naloxone
Supports withdrawal management
HPAModerate
Stress Response
Hypothalamic-Pituitary-Adrenal Axis
Attenuates stress responses
Reduces cortisol secretion
Improves stress coping
Unique Biological Properties
Unlike most peptides, DSIP freely crosses the blood-brain barrier and can be absorbed from the gut without enzymatic degradation. It's even present in human breast milk at 10-30 ng/mL concentrations.
Key distinction: DSIP promotes sleep without sedation — it supports natural sleep mechanisms rather than forcing unconsciousness
Multi-System Effects
Beyond sleep, DSIP influences thermoregulation, heart rate, blood pressure, pain threshold, and immune function. Effects are circadian-dependent and begin before behavioral signs of sleep appear.
Sleep Onset↑ Natural
Delta Waves↑ Enhanced
Pain Threshold↑ Elevated
Stress Response↓ Reduced
What Research Has Shown
Clinical trials and human studies
59%
Increase in Total Sleep Time Within 130 Minutes
Withdrawal Symptom Relief
Opiate Addicts-97%
Alcohol Addicts-87%
Trial details: 107 inpatients (60 opiate, 47 alcohol) received IV DSIP. Clinical symptoms and signs disappeared or improved markedly and rapidly in the vast majority of patients.
Clinical Outcomes
Response Rates Across Indications
Consistent efficacy across multiple conditions
97%of subjects
Showed symptom improvementOpiate withdrawal group
87%of subjects
Showed symptom improvementAlcohol withdrawal group
86%of subjects
Experienced pain reductionChronic pain patients
Key observation: DSIP's effects persisted for days after treatment, suggesting it 'reprograms' natural sleep patterns rather than providing temporary relief.
Beyond Sleep Enhancement
Multi-system benefits observed in research
59%
Sleep IncreaseTotal sleep time within 130 minutes
Healthy volunteers
Source97%
Withdrawal ReliefOpiate withdrawal symptoms
107 patients treated
Source86%
Pain ReductionChronic pain patients
6 of 7 responded
SourceNo
Exceptional SafetyNo lethal dose ever determined
Cannot kill animals
SourceSleep Architecture
Natural Sleep Promotion
DSIP promotes delta-wave (slow-wave) sleep without sedative effects, improving sleep quality and next-day performance
Delta Waves↑ Enhanced
Sleep Latency↓ Reduced
Sleep Efficiency↑ Improved
Daytime Alertness↑ Increased
Unique mechanism: Effects persist for several nights after treatment, suggesting circadian rhythm normalization
Stress & Mood
Stress Response Modulation
DSIP attenuates emotional and physiological stress responses while improving mood and coping behavior
Stress Reduction
+85%Mood Improvement
+75%Anxiety Relief
+65%Neuroprotection
Brain Protective Effects
Research demonstrates DSIP's ability to protect neurons and accelerate recovery from ischemic injury
Cerebral Ischemia↓ Mortality
Brain Edema↓ Reduced
Motor Recovery↑ Accelerated
Anticonvulsant↑ Threshold
Pain Management
Antinociceptive Effects
DSIP modulates pain perception through interactions with endogenous opioid systems
6/7
Chronic pain patients improved
Opioid interaction: Antinociceptive effect blocked by naloxone, indicating opioid receptor involvement
Dosing Information from Research
From human clinical trials
DSIP has been administered in various clinical trials via intravenous injection. The standard research dose is 25 nmol/kg body weight, with effects persisting for multiple days after administration.
Clinical Trial Protocol
Standard Clinical Protocol
Most commonly used in human studies
1-5DAY
25 nmol/kg
Daily IV injection
Loading phase
6-10DAY
25 nmol/kg
Every 48-72 hours
Maintenance phase
Administered via slow intravenous infusion
Effects persist for several days after each dose
No tolerance development observed
Daytime dosing still improves next night's sleep
Alternative Protocol
Subcutaneous Research Protocol
Alternative administration route
DailyFREQ
100-200 mcg
Before bed
Research setting
Subcutaneous administration studied in some protocols
Allows for at-home administration in research settings
May have different pharmacokinetic profile than IV
Pharmacokinetics
Pharmacokinetic Properties
Half-life7-8 minutes (plasma)
Blood-Brain BarrierFreely crosses
Oral BioavailabilityGut-absorbable
MetabolismAminopeptidases
Duration of EffectDays (circadian reset)
Short plasma half-life but prolonged biological effects
Effects on sleep persist for days after single dose
Present in human milk at 10-30 ng/mL
Important Notes
- Research protocols only — not approved for therapeutic use
- Short half-life but prolonged biological effects
- No tolerance development observed in studies
- Possible interaction with ACE inhibitors (share metabolic pathway)
Safety Profile from Research
Remarkably well-tolerated in human studies
DSIP demonstrates an exceptional safety profile. No lethal dose (LD50) has ever been determined because it has proven impossible to kill an animal with DSIP regardless of dose — a remarkable finding for any bioactive compound.
Common Digestive Issues
15%
Headache
mild
10%
Nausea
mild
8%
Vertigo/Dizziness
mild
5%
Daytime Grogginess
mild
Safety Profile
No Lethal Dose
DSIP's LD50 has never been determined because it has never proven possible to kill an animal regardless of the dose administered
- Exceptional safety margin
- No dependence or tolerance
- Naturally occurring endogenous peptide
Discontinuation Rates
Tolerability in Clinical Trials
Withdrawal studiesWell-tolerated
Insomnia studiesNo significant AEs
Pain studiesOccasional headaches
No tolerance development with repeated dosing
No withdrawal symptoms upon discontinuation
Naturally occurring peptide in human body
Trial Exclusions
Research Considerations
Caution with ACE inhibitors (shared metabolic pathway)Limited data on pregnancy/breastfeeding (present in milk)Drug interactions not extensively studiedLong-term effects require more research
Regulatory Status
Not FDA-approved for any indication
Research compound status
Used in clinical studies since 1977
Extensively studied but not commercialized
Researcher Notes
- Remarkably safe profile for a bioactive peptide
- No serious adverse events reported in published studies
- Naturally occurring substance found in human tissues
- Present in breast milk — indicating natural safety profile
Compound Information
Technical specifications
Molecular Profile
What Is DSIP?
Naturally occurring nonapeptide first isolated from rabbit brain in 1977
NonapeptideEndogenous
TypeSynthetic nonapeptide
CAS Number62568-57-4
Molecular FormulaC35H48N10O15
Molecular Weight848.8 g/mol
Amino Acids9 residues
SequenceTrp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Storage Requirements
Stability Information
Handle with care to maintain potency
Light sensitiveTemperature sensitive
Lyophilized (powder)
-20°C•protect from light
Reconstituted
2-8°C•use within 24 hours
Stability
15 minutes (plasma half-life)
Research Status
Development History
First isolated from rabbit brain in 1977 by Schoenenberger & Monnier
Discovery1977, Switzerland
DiscoverersSchoenenberger & Monnier
OriginRabbit mesodiencephalic ventricle
INN NameEmideltide
Human Studies1980s-present
Regulatory StatusResearch compound
Frequently Asked Questions
Common questions about DSIP research
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit brain in 1977 by Swiss researchers Schoenenberger and Monnier. It's synthesized in the hypothalamus and found in neurons, peripheral organs, and plasma throughout the body. The peptide is also present in human breast milk at concentrations of 10-30 ng/mL, suggesting a natural role in infant sleep regulation.
Unlike sedatives and hypnotics, DSIP promotes natural sleep rather than inducing chemical sedation. It enhances delta-wave (slow-wave) sleep architecture, improves sleep efficiency, and — remarkably — its effects persist for days after administration. DSIP doesn't cause dependence, tolerance, or withdrawal symptoms. Studies show improved daytime alertness and performance alongside better nighttime sleep.
Human clinical trials have demonstrated: 59% increase in total sleep time within 130 minutes (healthy volunteers); higher sleep efficiency and shorter sleep latency in chronic insomniacs (RCT); 97% symptom relief in opiate withdrawal and 87% in alcohol withdrawal (107 patients); and 86% response rate in chronic pain patients with simultaneous reduction in depression. Effects on sleep persist for multiple nights after single dosing.
DSIP has an exceptional safety profile. Most remarkably, no lethal dose (LD50) has ever been determined because researchers have never been able to kill an animal with DSIP regardless of the dose administered. Side effects in human studies are minimal — occasional transient headaches, nausea, or vertigo. No tolerance or dependence develops. As a naturally occurring endogenous peptide found in breast milk, DSIP appears to have inherent biological safety.
In clinical trials, DSIP is typically administered via slow intravenous infusion at 25 nmol/kg body weight. A common protocol involves daily injections for 5 days, followed by injections every 48-72 hours. Interestingly, daytime administration still improves nighttime sleep — the peptide appears to 'reset' circadian rhythms rather than directly inducing sedation. Subcutaneous administration has also been studied.
Beyond sleep, DSIP has demonstrated: antinociceptive (pain-relieving) effects blocked by naloxone, suggesting opioid pathway involvement; neuroprotective effects in stroke models with accelerated motor recovery; anticonvulsant activity with increased seizure threshold; stress attenuation and improved coping behavior; and antihypertensive effects in animal models. Research has explored its use in substance withdrawal, chronic pain, and neurological protection.
Despite promising clinical results since 1977, DSIP has never been commercialized as a pharmaceutical. This may be due to its short plasma half-life (7-8 minutes), challenges in drug delivery, or lack of patent protection for a naturally occurring peptide. It remains a research compound studied for its unique mechanism of promoting natural sleep without sedation.
Sources & References
Peer-reviewed research
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
